The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
Imatinib mesylate has become the gold standard front-line treatment of chronic myelogenous leukemia through its ability to inhibit ABL tyrosine kinase. Resistance to this inhibition may occur. We investigated the role of the K247R polymorphism in persistent sensitivity.
Nicolini
Franck Emmanuel
FE
Chabane
Kaddour
K
Cayuela
Jean-Michel
JM
Rousselot
Philippe
P
Thomas
Xavier
X
Hayette
Sandrine
S
D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D020125:Mutation, Missense; D010597:Pharmacogenetics; D010879:Piperazines / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics*; D011743:Pyrimidines / Q000494:pharmacology*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016315:Proto-Oncogene Proteins c-abl